METASTASIZED BRAIN CANCER TREATED WITH ISORAY`S CESIUM-131
IN WORLD`S FIRST AT N.Y. PRESBYTERIAN/WEILL CORNELL MEDICAL CENTER
Posted on: 10/10/2011
FOR IMMEDIATE RELEASE Contact: Sharon Schultz
Tel: (301) 351-0109
METASTASIZED BRAIN CANCER TREATED WITH ISORAY'S CESIUM-131
IN WORLD'S FIRST AT N.Y. PRESBYTERIAN/WEILL CORNELL MEDICAL CENTER
Richland, WA (September 26, 2011) - - IsoRay (AMEX: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, announced today that doctors at New York Presbyterian Hospital/ Weill Cornell Medical Center have performed the world's first treatment of metastasized brain cancer using IsoRay's Cesium-131 brachytherapy (internal radiation therapy) seeds. The seeds were implanted directly into a woman's brain to treat a cancer that had originated in the breast. Treatment of metastasized cancers, cancers that originate in other organs, is the latest application of IsoRay's pioneering brachytherapy treatment that represents one of the most important advancements in internal radiation therapy in the last 20 years.
Brain cancer treatment often involves removal of the brain tumor and then waiting several weeks while patients heal from the surgery before beginning external beam radiation treatment. However, delays in treatment can increase the chance of tumor recurrence. According to recent comments by New York Presbyterian Radiation Oncologist Dr. A. Gabriella Wernicke, M.D., M.Sc.,Cesium-131 offers an important alternative because it gives doctors the opportunity to act immediately. "By implanting the seeds into the surgical cavity right away, we essentially avoid the wait and therefore prevent the potential recurrence of the tumor at the surgical site," she explained. For a personal testimony, listen to the patient who received the first, groundbreaking treatment in her own words and learn more regarding the procedure at http://www.wptv.com/dpp/news/health/medical_breakthroughs/brain-seeds%3A-planting-tumor-fighters
Since the successful treatment of the first patient, doctors at New York Presbyterian/Weill Cornell Medical Center have expanded their use of IsoRay's patented Cesium-131 brachytherapy seeds to treat more than 20 other patients with recurrent Glioblastomas as well as metastasized brain cancer.
Cesium-131 offers many benefits over previously available alternatives. It does not require the many weeks of follow on treatment necessary in traditional external beam radiation, which involves numerous return trips to the hospital. In fact, Cesium-131 seeds deliver radiation quickly and aggressively compared to other types of internal, low dose rate radiation and limit damage to healthy surrounding tissues and organs. This is because of Cesium-131's shorter half life of 9.7 days compared to other radioactive isotopes used in internal radiation therapy. This pioneering treatment directly impacts longevity and the potential of recurrence, while improving quality of life and offering the opportunity for patients to return to normal activities more quickly.
IsoRay CEO Dwight Babcock says that he sees this as just the beginning. "The thought leaders at New York Presbyterian Hospital/ Weill Cornell Medical Center were among the early adopters of Cesium-131 because they were quick to recognize the important advantages Cesium-131 offers patients. I strongly believe that adoption of Cesium-131 for the treatment of primary and metastasized cancers will continue growing at an increasing rate as the medical community becomes aware of the significant advantages it offers in treating cancer sites throughout the body."
Babcock went on to say that the Company now has more than one leading-edge alternative to offer doctors and patients in their fight against brain cancer. "With the FDA's recent clearance of our GliaSite® balloon catheter internal radiation device and the application of Cesium-131 brachytherapy seeds, we now offer two powerful alternatives to fight this dreaded disease and help prevent its recurrence. This is a major advance in the war on cancer," he explained.
IsoRay is the exclusive manufacturer of Cesium-131. In addition to its CMS codes, Cesium-131 is FDA-cleared for the treatment of prostate cancer, lung cancer, ocular melanoma cancer, brain cancer, colorectal cancer, gynecological cancer, and head and neck cancer and other cancers throughout the body.
About IsoRay, Inc.
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com.
Safe Harbor Statement
Statements in this news release about IsoRay's future expectations, including: the advantages of our Cesium-131 seed, the advantages of the Cesium-131 seed brachytherapy application and the GliaSite® balloon catheter internal radiation device in brain cancer applications, whether IsoRay's Cesium-131 seed will be used to treat additional cancers and malignant disease, whether the use of Cesium-131 to treat brain cancers will be successful both long- and short-term in the initial and any future implants, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released and support the conclusions of early clinical studies, whether implants of Cesium-131 and use of the GliaSite® balloon catheter internal radiation device to treat brain cancers result in favorable patient outcomes, patient results achieved when Cesium-131 is used for the treatment of cancers and malignant diseases beyond prostate cancer, whether hospitals, medical treatment centers and physicians continue to adopt Cs-131 brachytherapy, successful completion of future research and development activities, and other risks detailed from time to time in IsoRay's reports filed with the SEC.
Click HERE to return to brain tumor news headlines